Literature DB >> 21586661

Short-course versus standard chemoradiation in T3 rectal cancer.

Theodore S Hong1, Harvey Mamon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21586661      PMCID： PMC3228203          DOI： 10.1634/theoncologist.2011-0052

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  21 in total

1.  Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer.

Authors:  E Kapiteijn; C A Marijnen; I D Nagtegaal; H Putter; W H Steup; T Wiggers; H J Rutten; L Pahlman; B Glimelius; J H van Krieken; J W Leer; C J van de Velde
Journal:  N Engl J Med       Date:  2001-08-30       Impact factor: 91.245

2.  Preoperative versus postoperative chemoradiotherapy for rectal cancer.

Authors:  Rolf Sauer; Heinz Becker; Werner Hohenberger; Claus Rödel; Christian Wittekind; Rainer Fietkau; Peter Martus; Jörg Tschmelitsch; Eva Hager; Clemens F Hess; Johann-H Karstens; Torsten Liersch; Heinz Schmidberger; Rudolf Raab
Journal:  N Engl J Med       Date:  2004-10-21       Impact factor: 91.245

3.  Adjuvant postoperative radiotherapy and chemotherapy in rectal carcinoma: a review of the Gastrointestinal Tumor Study Group experience.

Authors:  P R Thomas; A S Lindblad
Journal:  Radiother Oncol       Date:  1988-12       Impact factor: 6.280

4.  Adjuvant versus neoadjuvant radiochemotherapy for locally advanced rectal cancer. A progress report of a phase-III randomized trial (protocol CAO/ARO/AIO-94).

Authors:  R Sauer; R Fietkau; C Wittekind; P Martus; C Rödel; W Hohenberger; G Jatzko; H Sabitzer; J H Karstens; H Becker; C Hess; R Raab
Journal:  Strahlenther Onkol       Date:  2001-04       Impact factor: 3.621

5.  Effect of the circumferential resection margin on survival following rectal cancer surgery.

Authors:  S B Kelly; S J Mills; D M Bradburn; A A Ratcliffe; D W Borowski
Journal:  Br J Surg       Date:  2011-01-25       Impact factor: 6.939

6.  Circumferential margin involvement is still an important predictor of local recurrence in rectal carcinoma: not one millimeter but two millimeters is the limit.

Authors:  Iris D Nagtegaal; Corrie A M Marijnen; Elma Klein Kranenbarg; Cornelis J H van de Velde; J Han J M van Krieken
Journal:  Am J Surg Pathol       Date:  2002-03       Impact factor: 6.394

7.  Randomized phase 3 trial comparing preoperative and postoperative chemoradiotherapy with capecitabine for locally advanced rectal cancer.

Authors:  Jin-hong Park; Sang Min Yoon; Chang Sik Yu; Jong Hoon Kim; Tae Won Kim; Jin Cheon Kim
Journal:  Cancer       Date:  2011-02-15       Impact factor: 6.860

8.  Preoperative assessment of prognostic factors in rectal cancer using high-resolution magnetic resonance imaging.

Authors:  G Brown; A G Radcliffe; R G Newcombe; N S Dallimore; M W Bourne; G T Williams
Journal:  Br J Surg       Date:  2003-03       Impact factor: 6.939

9.  Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery.

Authors:  M J O'Connell; J A Martenson; H S Wieand; J E Krook; J S Macdonald; D G Haller; R J Mayer; L L Gunderson; T A Rich
Journal:  N Engl J Med       Date:  1994-08-25       Impact factor: 91.245

10.  Prolongation of the disease-free interval in surgically treated rectal carcinoma.

Authors: 
Journal:  N Engl J Med       Date:  1985-06-06       Impact factor: 91.245
View more
  1 in total

1.  Brachytherapy via a depot of biopolymer-bound 131I synergizes with nanoparticle paclitaxel in therapy-resistant pancreatic tumours.

Authors:  Jeffrey L Schaal; Jayanta Bhattacharyya; Jeremy Brownstein; Kyle C Strickland; Garrett Kelly; Soumen Saha; Joshua Milligan; Samagya Banskota; Xinghai Li; Wenge Liu; David G Kirsch; Michael R Zalutsky; Ashutosh Chilkoti
Journal:  Nat Biomed Eng       Date:  2022-10-19       Impact factor: 29.234
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.